0001209191-22-061408.txt : 20221215 0001209191-22-061408.hdr.sgml : 20221215 20221215160455 ACCESSION NUMBER: 0001209191-22-061408 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221213 FILED AS OF DATE: 20221215 DATE AS OF CHANGE: 20221215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lowrance David L CENTRAL INDEX KEY: 0001408498 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 221464804 MAIL ADDRESS: STREET 1: 422 WILLIAM WALLACE DRIVE CITY: FRANKLIN STATE: TN ZIP: 37064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 51285113796 MAIL ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-13 0 0001160308 Savara Inc SVRA 0001408498 Lowrance David L 6836 BEE CAVE ROAD BUILDING III, SUITE 201 AUSTIN TX 787846 0 1 0 0 CHIEF FINANCIAL OFFICER Common Stock 2022-12-13 4 A 0 100000 0.00 A 242793 D Stock Option (Right to Buy) 1.51 2022-12-13 4 A 0 250000 0.00 A 2032-12-13 Common Stock 250000 250000 D Represents restricted stock units ("RSUs") that vest in full on December 13, 2024, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 13, 2022, subject to the reporting person's continued service with the Issuer. /s/ David Lowrance 2022-12-15